Gabriella Hobbs, MD

Articles by Gabriella Hobbs, MD

Future of MF

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

February 16th 2024

Experts discuss how treatments, either monotherapy or combination, may impact the treatment landscape for MF and how they might choose among the new agents.

Combination Therapies for MF Management

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

February 9th 2024

Panel experts comment on the role of combination therapies in MF and debate if these therapies will be the new standard of care.

Future of PV: Unmet Needs

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

February 9th 2024

Faculty offer insights into the future of PV management as well as unmet needs.

Monitoring Patients on Myelofibrosis Treatment

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

February 2nd 2024

Faculty discuss the best strategies to monitor patients who are receiving treatment of MF as well as commenting on when it might be appropriate to switch therapies.

Treating Patients with Myelofibrosis and Anemia

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

February 2nd 2024

Expert oncologists provide insights into how they might manage patients who present with anemia and myelofibrosis in their practice.

Myelofibrosis: FDA Approved Treatment Options and Updates from ASH 2023

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

January 26th 2024

Overview of the current FDA approved treatment options for the management of myelofibrosis as well as reviewing recent updates from ASH 2023 on the SIMPLIFY and PERSIST trials.

Role of Transplant in Myelofibrosis

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

January 26th 2024

Panel experts comment on the role of transplant in patients with myelofibrosis.

MAJIC-PV: Clinical Implications in PV

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

January 19th 2024

Experts discuss the clinical implications of the MAJIC-PV trial.

Polycythemia Vera: Choosing the Right Treatment

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

January 19th 2024

Panel experts talk about when to use cytoreductive therapy and which factors influence their treatment selection as well as reviewing how patients with PV are monitored.

Polycythemia Vera: Treatment Goals and Options

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

January 12th 2024

Faculty discuss the treatment goals for patients diagnosed with polycythemia vera and review treatment options for managing PV.

REVEAL Study: Clinical Implications

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

January 12th 2024

Expert oncologists discuss the REVEAL study and provide their thoughts on these data and the impact in clinical practice.

Polycythemia Vera: Assessing Risk and Genetic Testing

ByGabriella Hobbs, MD,Andrew Kuykendall, MD,Prithviraj Bose, MD,Pankit Vachhani, MD,Ashwin Kishtagari, MD

January 12th 2024

Experts discuss the optimal strategy for NGS testing, which alterations to test for and how to assess for risk when diagnosing and managing patients with polycythemia vera (PV).